Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice

Vaccine

Volumn 28, Issue 4, 2010, Pages 934-939

  Little, S F ^a   Webster, W M ^a   Wilhelm, H ^a   Fisher, D ^a   Norris, S L W ^a   Powell, B S ^a   Enama, J ^a   Adamovicz, J J ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b MIDWEST RESEARCH INSTITUTE   (United States)

Author keywords

Yersinia pestis, Plague, F1 V vaccine, Mice, Serological correlate

Indexed keywords

F1 V VACCINE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SURVIVAL; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; MICE; PLAGUE; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; YERSINIA PESTIS;

EID: 73949132011     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.143     Document Type: Article

References (59)

1. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 1 (1997) 35-66
2. Baker E.E., Sommer H., Foster L.E., Meyer E., and Meyer K.F. Studies on immunization against plague. I. The isolation and characterization of the soluble antigen of Pasteurella pestis. J Immunol 68 (1952) 131-145
3. Burrows T.W., and Bacon G.A. The basis of virulence in Pasteurella pestis: an antigen determining virulence. Brit J Exp Pathol 37 (1956) 481-493
4. Meyer K.F., Hightower J.A., McCrumb F.R., Plague, and Immunization V.I. Vaccination with the Fraction 1 antigen of Yersinia pestis. J Infect Dis 129 Suppl. (1974) S41-S45
5. Une T., and Brubaker R.R. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol 133 4 (1984) 2226-2230
6. Nilles M.L., Fields K.A., and Straley S.C. The V antigen of Yersinia pestis regulates Yop vectorial targeting as well as Yop secretion through effects on YopB and LcrG. J Bacteriol 180 13 (1998) 3410-3420
7. Nakajima R., Motin V.L., and Brubaker R.R. Suppression of cytokines in mice by Protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 63 8 (1995) 3021-3029
8. Nedialkov Y.A., Motin V.L., and Brubaker R.R. Resistance to lipopolysaccharide mediated by the Yersinis pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect Immun 65 4 (1997) 1196-1203
9. Sing A., Rost D., Tvardovskaia N., Roggenkamp A., Wiedemann A., et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 196 (2002) 1017-1024
10. Welkos S., Friedlander A., McDowell D., Weeks J., and Tobery S. V antigen of Yersinia pestis inhibits neutrophil chemotaxis. Microb Pathogen 24 (1998) 185-196
11. Marketon M.M., DePaolo R.W., DeBord K.L., Jabri B., and Schneewind O. Plague bacteria target immune cells during infection. Science 309 (2005) 1739-1741
12. Lawton W., Erdman R., and Surgalla M. Biosynthesis and purification of V and W antigen in Pasteurella pestis. J Immunol 91 (1963) 179-184
13. Motin V.L., Nakajima R., Smirnov G.B., and Brubaker R.R. Passive immunity to Yersiniae mediated by anti-recombinant V antigen and Protein A-V antigen fusion peptide. Infect Immun 62 10 (1994) 4192-4201
14. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., et al. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63 8 (1995) 2854-2858
15. Anderson Jr. G.W., Leary S.E.C., Williamson E.D., Titball R.W., Welkos S.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64 11 (1996) 4580-4585
16. Roggenkamp A., Geiger A.M., Leitritz L., Kessler A., and Heesemann J. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect Immun 65 2 (1997) 446-451
17. Du Y., Rosqvist R., and Forsberg A. Role of Fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 70 3 (2002) 1453-1460
18. Williams Jr. R.C., Gewurz H., and Quie P.G. Effects of fraction I from Yersinia pestis on phagocytosis in vitro. J Infect Dis 126 3 (2007) 235-241
19. Simpson W.J., Thomas R.E., and Schwan T.G. Recombinant capsular antigen (Fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am J Trop Med Hyg 43 4 (1990) 389-396
20. Andrews G.P., Heath D.G., Anderson JrGW, Welkos S.L., and Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 64 6 (1996) 2180-2187
21. Anderson Jr. G.W., Worsham P.L., Bolt C.R., Andrews G.P., Welkos S.L., et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 56 (1997) 471-473
22. Winter C.C., Cherry W.B., and Moody M.D. An unusual strain of Pasteurella pestis isolated from a fatal human case of plague. Bull WHO 23 (1960) 408-409
23. Worsham P.L., Stein M.-P., and Welkos S.L. Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib Microbiol Immunol 13 (1995) 325-328
24. Welkos S.L., Davis K.M., Pitt L.M., Worsham P.L., and Friedlander A.M. Studies on the contribution of the F1 capsule-associated plasmid pFra to the virulence of Yersinia pestis. Contrib Microbiol Immunol 13 (1995) 299-305
25. Meyer K.F. Effectiveness of live or killed plague vaccines in man. Bull WHO 42 (1970) 635-666
26. Meyer K.F., Cavanaugh D.C., Bartelloni P.J., and Marshal Jr. J.D. Plague Immunization. I. Past and present trends. J Infect Dis 129 Suppl. (1974) S13-S18
27. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 (1995) 223-230
28. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11/12 (1998) 1131-1137
29. Williams J.E., and Cavanaugh D.C. Measuring the efficacy of vaccination in affording protection against plague. Bull WHO 57 2 (1979) 309-313
30. Russell P., Eley S.M., Hibbs S.E., Manchee R.J., Stagg A.J., et al. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13 16 (1995) 1551-1556
31. Anderson Jr. G.W., Heath D.G., Bolt C.R., Welkos S.L., and Friedlander A.M. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice. Am J Trop Med Hyg 58 6 (1998) 793-799
32. Williamson E.D., Vesey P.M., Gillhespy K., Eley S.M., Green M., et al. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116 (1999) 107-114
33. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., et al. Design and testing for a non-tagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 (2005) 1490-1510
34. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 10 (1997) 1079-1084
35. Andrews G.P., Strachan S.T., Benner G.E., Sample A.K., Anderson Jr. G.W., et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect Immun 67 3 (1999) 1533-1537
36. Swietnicki W., Powell B.S., and Goodin J. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague. Protein Expr Purif 42 (2005) 166-172
37. Goodin J.L., Raab R.W., McKown R.L., Coffman G.L., Powell B.S., et al. Yersinia pestis outer membrane type III secretion protein YscC: expression, purification, characterization, and induction of specific antiserum. Protein Expr Purif 40 (2005) 152-163
38. Matson J.S., Durick K.A., Bradley D.S., and Nilles M.L. Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol 5 (2005) 38
39. Wang S., Joshi S., Mboudjeka I., Liu F., Ling T., et al. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine 26 (2008) 1664-1674
40. Leary S.E.C., Griffin K.F., Galyov E.E., Hewer J., Williamson E.D., et al. Yersinia outer proteins (YOPS) E, K and N are antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb Pathogen 26 (2008) 159-169
41. Murphy B.S., Wulff C.R., Garvy B.A., and Straley S.C. Yersinia pestis YadC: a novel vaccine candidate against plague. Adv Exp Med Biol 603 (2007) 400-414
42. - Yersinia pestis. Infect Immun 76 11 (2008) 5181-5190
43. Williamson E.D., Flick-Smith H.C., LeButt C., Rowland C.A., Jones S.M., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 73 (2005) 3598-3608
44. Irving M., Packer P., Miller J., Brooks T.J., Fuhr R., et al. Two phase I clinical trials of a recombinant F1 and V plague vaccine. ASM biodefense and emerging diseases research meeting. Washington, DC, February 27-March 2 (2007) 38 [Abstract 080(E)]
45. Morris S.R. Development of a recombinant vaccine against aerosolized plague. Vaccine 25 (2007) 3115-3117
46. Welkos S., Norris S., and Adamovicz J. Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. Clin Vacc Immunol 15 (2008) 1134-1137
47. Speck R.S., and Wolochow H. Studies on the experimental epidemiology of respiratory infections. VIII. Experimental pneumonic plague in Macacus rhesus. J Infect Dis 100 (1957) 58-69
48. von Metz E., Eisler D.M., and Hottle G.A. Immunogenicity of plague vaccines in mice and guinea pigs. Appl Microbiol 22 (1971) 84-88
49. Chen T.H., Foster L.E., and Meyer K.F. Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs. J Infect Dis 129 Suppl. (1974) S53-S61
50. Little S.F., Webster W.M., Wilhelm H., Powell B., Enama J., et al. Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice. Biologicals 36 (2008) 287-295
51. Lacy M.J., and Voss Jr. E.W. A modified method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells. J Immunol Meth 87 (1986) 169-177
52. Bliss C.I. Provisionally normal distributions. Statistics in biology, Statistical methods for research in the natural sciences vol. 1 (1967), McGraw-Hill, New York 152-185
53. Friedlander A.M., Welkos S.L., Worsham P.L., Andrews G.P., Heath D.G., et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 21 Suppl. 2 (1995) S178-S181
54. Davis K.J., Fritz D.L., Pitt M.L., Welkos S.L., Worsham P.L., et al. Pathology of experimental pneumonic plague produced by Fraction 1-positive and Fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 120 (1996) 156-163
55. Sebbane F., Jarrett C., Gardner D., Long D., and Hinnebusch B.J. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bit in a mouse model of bubonic plague. Infect Immun 77 (2009) 1222-1229
56. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., et al. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19 (2001) 566-571
57. Williamson E.D., Stagg A.J., Eley S.M., Taylor R., Green M., et al. Kinetics of the immune response to the (F1 + V) vaccine in models of bubonic and pneumonic plague. Vaccine 25 (2007) 1142-1148
58. Zauberman A., Cohen S., Levy Y., Halperin g, Lazar S., et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 26 (2008) 1616-1625
59. Bashaw J., Norris S., Weeks S., Trevino S., Adamovicz J., et al. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vacc Immunol 14 (2007) 605-616